EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Acanthamoeba keratitis Standard, problems, and new approaches



Treatment of Acanthamoeba keratitis Standard, problems, and new approaches



Wiener Klinische Wochenschrift 115(Supplementum 3): 10-17



Acanthamoeba keratitis is a corneal disease associated predominantly with contact lens wear. The occurrence of Acanthamoeba keratitis has been rising since 1990 in correlation to the growing number of contact lens wearers. To date approximately 2000 cases have been published around the world. Due to the complicated diagnostics, the elaborate treatment and the usually bad compliance of the patients, Acanthamoeba keratitis unfortunately very often takes a serious progression, which may lead to serious visual loss and perforating keratoplasty. Today, local treatment with a combination of polyhexamethylene biguanide (PHMB) and propamidine isethionate (Brolene) is considered the first line therapy for Acanthamoeba keratitis. Alternatively also a combination of propamidine and chlorhexidine or neomycine achieves good therapeutic results. However, the complicated mode of application consistently remains a problem. The intensive local treatment, i.e. hourly application of therapeutics during the first three days day and night makes hospitalization inevitable. Moreover, sufficient efficacy can not always be achieved, and also resistance against propamidine has already been observed. Recently propamidine has sometimes been replaced by hexamidine, which seems to have a greater cysticidal activity. A new path might be struck by the application of alkylphosphocholines. These are phosphocholines esterified to aliphatic alcohols. They exhibit in vitro and in vivo antineoplastic activity and have been shown to be cytotoxic against Leishmania donovani, Trypanosoma cruzi, and Entamoeba histolytica. A recent study has demonstrated that particularly hexadecylphosphocholine is highly effective also against various strains of Acanthamoeba.

(PDF emailed within 1 workday: $29.90)

Accession: 035980322

Download citation: RISBibTeXText



Related references

Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches. Wiener Klinische Wochenschrift 115 Suppl 3: 10-17, 2004

Acanthamoeba keratitis: multicentre survey in England 1992-6. National Acanthamoeba Keratitis Study Group. British Journal of Ophthalmology 82(12): 1387-1392, 1999

Acanthamoeba keratitis in Austria Acanthamoeba-keratitis in Oesterreich Klinische, mikrobiologische un epidemiologische Befunde. Mitteilungen der Oesterreichischen Gesellschaft fuer Tropenmedizin und Parasitologie, 23: 17-25, 2001

Effect of immunization with the mannose-induced Acanthamoeba protein and Acanthamoeba plasminogen activator in mitigating Acanthamoeba keratitis. Investigative Ophthalmology & Visual Science 48(12): 5597-5604, 2007

Acanthamoeba keratitis cluster: an increase in Acanthamoeba keratitis in Australia. Clinical & Experimental Ophthalmology 37(2): 181-190, 2009

Treatment of Acanthamoeba keratitis. South African Medical Journal 86(5): 566-566, 1996

Treatment of Acanthamoeba keratitis. Cornea 17(1): 11-16, 1998

Treatment of acanthamoeba keratitis with chlorhexidine. Ophthalmology 106(4): 798-802, 1999

Keratoplasty for treatment of Acanthamoeba keratitis. Ophthalmology 116(5): 864-869, 2009

Drug-resistant severe Acanthamoeba keratitis caused by rare T5 Acanthamoeba genotype. Eye & Contact Lens 36(3): 183-184, 2010

Genotyping of Acanthamoeba isolates and clinical characteristics of patients with Acanthamoeba keratitis in China. Journal of Medical Microbiology 59(Pt 4): 462-466, 2010

Influence of Acanthamoeba genotype on clinical course and outcomes for patients with Acanthamoeba keratitis in Spain. Journal of Clinical Microbiology 52(4): 1213-1216, 2015

Characterization of secreted proteinase of Acanthamoeba castellanii and its role in pathogenesis of Acanthamoeba keratitis. Investigative Ophthalmology & Visual Science 38(4 PART 1-2): S1073, 1997

Acanthamoeba keratitis due to Acanthamoeba genotype T4 in a non-contact-lens wearer in Turkey. Parasitology Research 100(2): 241-246, 2006

Acanthamoeba keratitis: improving the Scottish diagnostic service for the rapid molecular detection of Acanthamoeba species. Journal of Medical Microbiology 64(7): 682-687, 2015